Barcelona, November 26th, 2026

INSIDER INFORMATION

Simcere and Almirall announce IL-2mu-Fc (SIM0278) meets the primary endpoint at week 16 in Phase II atopic dermatitis study

In accordance with Securities Markets Law, Almirall S.A. ("Almirall") announces the following:

The study, conducted by Simcere, showed that SIM0278, an interleukin 2 mutant fusion protein (IL-2mu-Fc) met the primary endpoint, delivering statistically significant improvements in disease severity at week 16.

One of the two key secondary endpoints was met, while the other showed numerical improvement.

The study is ongoing and will continue through week 52 with detailed results expected to be presented at a future scientific congress.

Almirall and Simcere's licensing partnership combines Simcere's IL-2mu-Fc programme with Almirall's deep expertise in medical dermatology.

Sincerely,

Pablo Divasson del Fraile
Investor Relations Department
investors@almirall.com